Posttranslational Modifications of RAS Proteins.
| Autor: | Ahearn I; Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, New York 10016., Zhou M; Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, New York 10016., Philips MR; Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, New York 10016. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cold Spring Harbor perspectives in medicine [Cold Spring Harb Perspect Med] 2018 Nov 01; Vol. 8 (11). Date of Electronic Publication: 2018 Nov 01. |
| DOI: | 10.1101/cshperspect.a031484 |
| Abstrakt: | The three human RAS genes encode four proteins that play central roles in oncogenesis by acting as binary molecular switches that regulate signaling pathways for growth and differentiation. Each is subject to a set of posttranslational modifications (PTMs) that modify their activity or are required for membrane targeting. The enzymes that catalyze the various PTMs are potential targets for anti-RAS drug discovery. The PTMs of RAS proteins are the focus of this review. (Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|